Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Casdatifan (AB521) in Healthy Volunteers
NCT05117554Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of casdatifan in clear cell renal cell carcinoma (ccRCC) (5 arms), sponsored by Arcus Biosciences. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events up to 21.5 Weeks, Maximum Observed Plasma Concentration of Casdatifan up to 21.5 Weeks and 1 more. Started Nov 2021; status: completed.
02
Drugs
casdatifan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05117554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117554.